Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
In this trial, patients with severe sepsis and low protein C levels will receive drotrecogin
alfa (activated) at the normal, approved dose and time of administration [24
microgram/kilogram/hour (mcg/kg/hour) for 96 hours] or will receive the normal, approved dose
or higher doses than the approved dose for a longer administration time. After the drug
administration is complete, the protein C levels from the patients receiving the normal,
approved dose will be compared to protein C levels from patients receiving the normal,
approved dose or higher dose for a longer duration to determine if the protein C levels
improve faster if given higher dose and/or longer administration time.
Note: The protocol was amended to remove the option of shorter infusion durations.